Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

NCT02739360 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02739360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02739360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
Lead sponsor
Gilead Sciences
Phase
Phase 4
Overall status
Terminated
Start date
May 4, 2016
Completion date
December 28, 2017
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoid malignancies